TLX101 CDx
Alternative Names: 18F-floretyrosine; 18F-FET; O-(2-[18F]fluoroethyl)-L-tyrosine; Pixclara; Pixlumi; TLX 101-Cdx; TLX101-PxLatest Information Update: 23 Feb 2026
At a glance
- Originator Telix Pharmaceuticals
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Yes - Glioma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Glioblastoma
Most Recent Events
- 18 Feb 2026 Preregistration for Glioblastoma (Diagnosis) in European Union (IV)
- 18 Feb 2026 Telix Pharmaceuticals plans to launch TLX101 CDx in Europe for the characterization of glioma
- 22 Dec 2025 Telix Pharmaceuticals completes a Type A meeting with the US FDA to review the basis of the Complete Response Letter for New Drug Application (NDA) resubmission